DoD P&T Committee - Review of Hepatitis C Direct Acting Agents; Request for Provider Opinion

The DoD Pharmacy and Therapeutics Committee is considering a future review of the Hepatitis C (HCV) Direct  Acting Agents (DAA) class. These medications accounted for approximately $84 million in expenditures from Aug 2015 - Jul 2016.   If reviewed,  DoD P&T Committee will determine which drugs should be designated BCF, UF or non-formulary on the Uniform Formulary. 

 

As a health care provider, your input is very important to us, and we would like to know your opinions from completing the questions below before a potential review. The survey consists of 24 questions and should take less than 15 minutes to complete. Please complete the survey by 25 November 2016, and thank you in advance for taking the time to complete this important survey!

Class Notes: This review will focus on the HCV DAA only.   Epclusa (sofosbuvir/velpatasvir), Harvoni(sofosbuvir/ledipasvir), Technivie (ombitasvir/paritaprevir/ritonavir), Viekira Pak (dasabuvir and ombitasvir/paritaprevir/ritonavir), Viekira XR (dasabuvir/ombitasvir/paritaprevir/ritonavir) and Zepatier (elbasvir/grazoprevir) are the six combination agents that can be used as monotherapy.  The three “single-agent” brands that must be used in combination with another HCV agent are Daklinza (daclatasvir), Olysio (simeprevir) and Sovaldi (sofosbuvir). 

 

BCF (green) = Basic core formulary = MTFs must have these on their local formulary

UF (yellow) = Uniform formulary = MTFs may have these on their local formulary

NF (red) = Non-formulary = MTFs must not have these on their local formulary